Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$1.15 -5.0%	$1.02	$0.40 ▼ $1.79	$19.29M	0.06	297,373 shs	169,464 shs
ALXO ALX Oncology	$0.46 -3.2%	$0.54	$0.41 ▼ $13.39	$24.76M	1.21	989,642 shs	368,538 shs
CLNN Clene	$2.37 -3.3%	$2.99	$2.28 ▼ $9.20	$21.29M	0.46	81,745 shs	157,240 shs
NLSP NLS Pharmaceutics	$1.85 -5.1%	$1.54	$1.30 ▼ $18.39	$6.66M	-0.21	871,720 shs	306,866 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	0.00%	-22.30%	+26.23%	+64.38%	+7.48%
ALXO ALX Oncology	0.00%	+6.01%	-22.85%	-58.41%	-96.91%
CLNN Clene	0.00%	-7.78%	-25.24%	-46.50%	-67.46%
NLSP NLS Pharmaceutics	0.00%	+14.47%	+23.33%	-5.13%	+1,056.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.2008 of 5 stars	0.0	3.0	0.0	0.0	1.1	0.8	0.0
ALXO ALX Oncology	3.4798 of 5 stars	4.4	2.0	0.0	0.0	2.0	3.3	1.3
CLNN Clene	2.0791 of 5 stars	3.6	3.0	0.0	0.0	0.0	2.5	0.6
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
ALXO ALX Oncology	2.71	Moderate Buy	$3.30	611.67% Upside
CLNN Clene	3.17	Buy	$40.00	1,587.76% Upside
NLSP NLS Pharmaceutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NLSP, ABVC, CLNN, and ALXO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	ALXO ALX Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1.20 ➝ $1.00
5/9/2025	ALXO ALX Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/12/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/12/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$508.38K	37.94	N/A	N/A	$1.02 per share	1.13
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$3.81 per share	N/A
CLNN Clene	$350K	60.83	N/A	N/A	$2.09 per share	1.13
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$10.52M	-$0.13	N/A	∞	N/A	-1,619.65%	-104.94%	-56.81%	8/12/2025 (Estimated)
ALXO ALX Oncology	-$160.80M	-$2.47	N/A	N/A	N/A	N/A	-93.02%	-70.67%	N/A
CLNN Clene	-$49.50M	-$4.04	N/A	N/A	N/A	-8,556.77%	-1,106.30%	-85.11%	8/6/2025 (Estimated)
NLSP NLS Pharmaceutics	-$12.17M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest NLSP, ABVC, CLNN, and ALXO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ALXO ALX Oncology	-$0.47	-$0.58	-$0.11	-$0.58	N/A	N/A
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million
4/30/2025	Q4 2024	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A
4/15/2025	Q4 2024	ABVC ABVC BioPharma	N/A	$0.04	N/A	$0.04	N/A	N/A
3/24/2025	Q4 2024	CLNN Clene	-$1.21	-$1.67	-$0.46	-$1.67	$0.13 million	$0.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
NLSP NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.34	0.34
ALXO ALX Oncology	0.07	4.82	4.82
CLNN Clene	N/A	0.83	0.82
NLSP NLS Pharmaceutics	N/A	0.15	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ALXO ALX Oncology	97.97%
CLNN Clene	23.28%
NLSP NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	11.90%
ALXO ALX Oncology	33.40%
CLNN Clene	35.30%
NLSP NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.77 million	11.43 million	Not Optionable
ALXO ALX Oncology	40	53.40 million	35.13 million	Optionable
CLNN Clene	100	8.98 million	6.24 million	Optionable
NLSP NLS Pharmaceutics	6	3.60 million	3.01 million	Not Optionable

NLSP, ABVC, CLNN, and ALXO Headlines

Recent News About These Companies

NLS Pharmaceutics to present Mazindol study at ASCP Meeting

May 23 at 12:06 AM | investing.com

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

May 21, 2025 | prnewswire.com

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

April 15, 2025 | prnewswire.com

NLS Pharmaceutics, Kadimastem announce up to $3M equity financing

April 1, 2025 | markets.businessinsider.com

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

March 31, 2025 | accessnewswire.com

NLS Pharmaceutics CEO Issues Letter to Shareholders

March 10, 2025 | prnewswire.com

NLS Pharmaceutics announces new preclinical data for AEX-2

February 27, 2025 | markets.businessinsider.com

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

February 27, 2025 | prnewswire.com

NLS Pharmaceutics and Kadimastem complete pre-IND diabetes meeting with FDA

February 25, 2025 | markets.businessinsider.com

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

February 25, 2025 | prnewswire.com

NLS Pharmaceutics files $75M mixed securities shelf

February 11, 2025 | markets.businessinsider.com

NLS and Kadimastem to merge, aim for diabetes care innovation

February 10, 2025 | msn.com

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

February 10, 2025 | prnewswire.com

NLS Pharmaceutics files to sell 645,161 common shares for holders

February 5, 2025 | markets.businessinsider.com

NLS Pharmaceutics AG (NLSP) Stock: Analyzing Its Quiet Power

February 3, 2025 | bovnews.com

Kadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

January 31, 2025 | finanznachrichten.de

NLS Pharmaceutics’ merger approved by Kadimastem shareholders

January 31, 2025 | markets.businessinsider.com

NLS Gains on Deal with Kardimastem

January 31, 2025 | baystreet.ca

NLS and Kadimastem move forward with merger plans

January 31, 2025 | msn.com

NLS Pharmaceutics Stock Rises 29% Following Merger Announcement With Kadimastem

January 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLSP, ABVC, CLNN, and ALXO Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$1.15 -0.06 (-4.96%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.14 0.00 (-0.43%)

As of 05/23/2025 06:58 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

ALX Oncology NASDAQ:ALXO

$0.46 -0.02 (-3.17%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$0.48 +0.02 (+3.95%)

As of 05/23/2025 07:56 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Clene NASDAQ:CLNN

$2.37 -0.08 (-3.27%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$2.39 +0.02 (+0.84%)

As of 05/23/2025 06:51 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

NLS Pharmaceutics NASDAQ:NLSP

$1.85 -0.10 (-5.13%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$1.89 +0.04 (+2.16%)

As of 05/23/2025 07:54 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time